Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07776964 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Monitoring for CardioToxicity Using WeArable deVices While Undergoing cancEr Treatments (MCT-WAVE)

StatusNot Yet Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date pushed from Sep 15, 2026 to Oct 29, 2026
    • Eligibility criteria expanded, about 8 words
  2. Start date: Sep 1, 2026 to Sep 15, 2026v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This pilot study will evaluate the validity and feasibility of ambulatory cardiac monitoring to identify markers of cardiotoxicity in adults undergoing cancer treatment. Participants with breast cancer, hematologic malignancy, or multiple myeloma will receive usual care plus two wearable patch monitors: mobile cardiac telemetry using the BodyGuardian Mini Plus ambulatory ECG monitor and an investigational wearable cardiac monitor that records heart sounds. The study will assess arrhythmias detected by mobile cardiac telemetry and explore whether heart sounds are associated with echocardiographic findings and cardiac biomarkers. Participants will wear the devices during cancer treatment, with monitoring periods at baseline and possible repeat monitoring at 6-month and 12-month study visits.
Trial Details
NCT Number NCT07776964
Lead Sponsor University of Minnesota
Collaborators: Boston Scientific Corporation
Conditions
(from sponsor)		 Cardiotoxicity, Cancer, Cardiac Arrhythmia, Left Ventricular Dysfunction, Breast Cancer, Multiple Myeloma
Related terms Arrhythmias, Cardiac, Breast Neoplasms, Cardiotoxicity, Multiple Myeloma, Neoplasms, Ventricular Dysfunction, Left
Enrollment 72 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov